• Home
  • Sitemap
  • Help
  • Technical Support
  • Contact
DNA Regulation / Transcription
You are here: Product Lines > DNA Regulation / Transcription
 
Toolbar - View Selection
 
 Items 160-180 of 694 Page 9 of 35 Select Page: << 1 2 3 4 5 6 7 8 9 10  >>  
ALX-350-092 Revised 03-Apr-08
Emetine . dihydrochloride
Add to Clipboard
SYNONYMS 6’,7’,10,11-Tetramethoxyemetan . 2HCl
PRODUCT LINE Natural Products / Antibiotics
PRODUCT CATEGORY Natural Products - DNA Replication Inhibitors
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-350-092-M050   50 mg 10.00 USD Add To Cart
Product Specification
FORMULA: C29H40N2O4 . 2HCl
MW: 480.7 . 73.0
CAS NUMBER: 316-42-7
MERCK INDEX: 14: 3559
SOURCE/HOST: Isolated from ground roots of Uragoga ipecacuanha.
PURITY: ≥98%
APPEARANCE: White to off-white solid.
SOLUBILITY: Soluble in water or 100% ethanol.
SHIPPING: AMBIENT
LONG TERM STORAGE: +4°C
HANDLING: Protect from light. Hygroscopic.
HAZARD: TOXIC.

Product Description
Irreversibly blocks protein synthesis by inhibiting the movement of ribosome along the mRNA. Induces hypotension by blocking adrenoreceptors. Inhibits DNA replication in the early S phase. Inhibits HIF-1 activation by hypoxia. Induces apoptosis in leukemia cells. Antiamebic.
Product Specific Literature References
Inhibitors of protein biosynthesis. V. Effects of emetine on protein and nucleic acid biosynthesis in HeLa cells: A.P. Grollman; J. Biol. Chem. 243, 4089 (1968) Abstract
Cytometric analysis of DNA replication inhibited by emetine and cyclosporin A:: A: T. Schweighoffer, et al.; Histochemistry 96, 93 (1991) Abstract
Emetine allows identification of origins of mammalian DNA replication by imbalanced DNA synthesis, not through conservative nucleosome segregation: W.C. Burhans, et al.; EMBO J. 10, 4351 (1991) Abstract
Role of newly synthesized MHC class II molecules in antigen-specific antigen presentation by B cells: T. Kokuho, et al.; Immunobiology 193, 42 (1995) Abstract
Terpenoid tetrahydroisoquinoline alkaloids emetine, klugine, and isocephaeline inhibit the activation of hypoxia-inducible factor-1 in breast tumor cells: Y.D. Zhou, et al.; J. Nat. Prod. 68, 947 (2005) Abstract
The alkaloid emetine as a promising agent for the induction and enhancement of drug-induced apoptosis in leukemia cells: M. Moller, et al.; Oncol. Rep. 18, 737 (2007) Abstract
Characteristics of apoptosis induction by the alkaloid emetine in human tumour cell lines: M. Moller & M. Wink; Planta Med. 73, 1389 (2007) Abstract
Further Categories Containing This Product:
Other Toxins • Hypoxia-inducible Factor [HIF]/Related Products • Alkaloids • Parasitic Diseases Other Products • Adrenergics & Adrenergic Receptors/Related Products • DNA Replication Inhibitors • Translation Inhibitors • Natural Products - Other Anti-infective Agents • Natural Products - Apoptosis Inducers & Inhibitors • Natural Products for Neurological Research
 
 
ALX-350-057 Revised 20-Feb-08
Emodin
Add to Clipboard
SYNONYMS 6-Methyl-1,3,8-trihydroxyanthraquinone
PRODUCT LINE Natural Products / Antibiotics
PRODUCT CATEGORY Natural Products - Protein Kinase Inhibitors
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-350-057-M025   25 mg 45.00 USD Add To Cart
Product Specification
FORMULA: C15H10O5
MW: 270.2
CAS NUMBER: 518-82-1
MERCK INDEX: 14: 3561
RTECS: CB7920600
SOURCE/HOST: Isolated from Frangula bark.
PURITY: ≥96% (HPLC)
APPEARANCE: Orange to red solid.
SOLUBILITY: Soluble in DMSO, 100% ethanol or 1N dilute aqueous ammonia; insoluble in water.
SHIPPING: AMBIENT
LONG TERM STORAGE: +4°C
HAZARD: IRRITANT.

Product Description
Inhibitor of p56lck tyrosine kinase. Has mutagenic and genotoxic effects, mainly in bacterial systems. Anticancer agent. Exhibits anti-proliferative effects in various cancer cell lines by efficient induction of apoptosis. Has inhibitory effects on angiogenic and metastasis regulatory processes. Anti-inflammatory compound. Suppresses NF-κB activation. 
Product Specific Literature References
Emodin, a protein tyrosine kinase inhibitor from Polygonum cuspidatum: H. Jayasuriya, et al.; J. Nat. Prod. 55, 696 (1992) Abstract
Selective inhibition of the growth of ras-transformed human bronchial epithelial cells by emodin, a protein-tyrosine kinase inhibitor: T.C.K. Chan, et al.; BBRC 193, 1152 (1993) Abstract
Molecular mechanism of emodin action: transition from laxative ingredient to an antitumor agent: G. Srinivas, et al.; Med. Res. Rev. 27, 591 (2007), (Review) Abstract
Further Categories Containing This Product:
Tyrosine Kinase Inhibitors • Other Toxins • Kinases in T Cell Signal Transduction/Related Products • Src Family Kinases/Related Products • Natural Products - Anti-inflammatory Agents • Natural Products - Antitumor Reagents • NF-kB Pathway Inhibitors • Natural Products - NF-kB Pathway Inhibitors • Natural Products - Apoptosis Inducers & Inhibitors
 
 
ALX-201-244 Revised 27-Mar-07
Endonuclease G (human) (recombinant)
Add to Clipboard
SYNONYMS EndoG (human) (recombinant)
PRODUCT LINE Cell Death / Apoptosis / Autophagy
PRODUCT CATEGORY HtrA2/Omi, ARTS, EndoG/Related Products
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-201-244-C020   20 µg 190.00 USD Add To Cart
Product Specification
SOURCE/HOST: Produced in E. coli. Recombinant human endonuclease G is fused to a His-tag at the C-terminus.
CONCENTRATION: 0.4mg/ml
PURITY: ≥90% (SDS-PAGE)
FORMULATION: Liquid. In 50mM TRIS-HCl, pH 8.0, containing 500mM sodium chloride, 0.05% Tween 20, 5mM β-mercaptoethanol, 500mM imidazole and 20% glycerol.
SHIPPING: SHIPPED ON DRY ICE
LONG TERM STORAGE: -80°C
HANDLING: Avoid freeze/thaw cycles. After opening, prepare aliquots and store at -80°C.
Product Images
Please click on thumbnails to enlarge.
Further Categories Containing This Product:
Recombinant Proteins/Fusion Proteins • DNA Endonucleases/Related Products
 
 
ALX-201-230 Revised 26-Apr-06
Endonuclease G (rat) (recombinant)
Add to Clipboard
SYNONYMS EndoG (rat) (recombinant)
PRODUCT LINE Cell Death / Apoptosis / Autophagy
PRODUCT CATEGORY HtrA2/Omi, ARTS, EndoG/Related Products
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-201-230-C020   20 µg 190.00 USD Add To Cart
Product Specification
CONCENTRATION: 0.4mg/ml
PURITY: ≥90% (SDS-PAGE)
FORMULATION: Liquid. In 50mM TRIS-HCl, pH 8.0, containing 500mM sodium chloride, 0.05% Tween 20, 5mM β-mercaptoethanol, 500mM imidazole and 20% glycerol.
SHIPPING: SHIPPED ON DRY ICE
LONG TERM STORAGE: -80°C
HANDLING: Avoid freeze/thaw cycles. After opening, prepare aliquots and store at -80°C.
Further Categories Containing This Product:
Recombinant Proteins/Fusion Proteins • DNA Endonucleases/Related Products
 
 
ALX-380-290 Revised 15-Apr-08 New product
Enrofloxacin
Add to Clipboard
SYNONYMS 1,4-Dihydro-1-cyclopropyl-7-(4-ethyl-1-piperazinyl)-6-fluoro-4-oxo-3-quinolinecarboxylic acid
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-380-290-G005   5 g 30.00 USD Add To Cart
ALX-380-290-G025   25 g 120.00 USD Add To Cart
Product Specification
FORMULA: C19H22FN3O3
MW: 359.4
CAS NUMBER: 93106-60-6
MERCK INDEX: 14: 3592
RTECS: VB1993650
PURITY: ≥98% (Assay)
APPEARANCE: White to light yellow crystalline powder.
SOLUBILITY: Slightly soluble in water.
SHIPPING: AMBIENT
LONG TERM STORAGE: -20°C

Product Description

Fluoroquinolone with broad spectrum activity against Gram-negative and Gram-positive bacteria as well as against Mycoplasma spp. Inhibits bacterial DNA-gyrase (topoisomerase).
Product Specific Literature References
Enrofloxacin: a new antimicrobial agent: J. Schroder; J. S. Afr. Vet. Assoc. 60, 122 (1989) Abstract
Further Categories Containing This Product:
Antibiotics - DNA Replication Inhibitors • Antibiotics - Topoisomerase Inhibitors
 
 
ALX-350-254 Revised 10-Mar-08
Epoxomicin
Add to Clipboard
PRODUCT LINE Natural Products / Antibiotics
PRODUCT CATEGORY Antibiotics - Proteasome/Ubiquitin Modulators
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-350-254-C050   50 µg 132.00 USD Add To Cart
Product Specification
FORMULA: C28H50N4O7
MW: 554.7
CAS NUMBER: 134381-21-8
MERCK INDEX: 14: 3630
SOURCE/HOST: Synthetic.
PURITY: ≥95% (HPLC)
APPEARANCE: White to off-white solid.
SOLUBILITY: Soluble in DMSO (15mg/ml); insoluble in water.
ACTIVITY: kobs/[I] = 25’000M-1s-1 versus 20S proteasome.
SHIPPING: AMBIENT
LONG TERM STORAGE: -20°C
HANDLING: Avoid freeze/thaw cycles. Protect from light.
IDENTITY: Identity determined by 1H-NMR.

Product Description
Cell permeable, potent and selective proteasome inhibitor originally isolated from Actinomycetes strain based on its potent in vivo antitumor activity. More potent inhibitor of the chymotrypsin-like activity of the proteasome than lactacystin. Effectively inhibits NF-κB activation in vitro and potently blocks inflammation in vivo in the mouse ear edema assay.
Product Specific Literature References
Epoxomicin, a new antitumor agent of microbial origin: M. Hanada, et al.; J. Antibiot. (Tokyo) 45, 1746 (1992) Abstract
Proteasome inhibition by the natural products epoxomicin and dihydroeponemycin: insights into specificity and potency: K.B. Kim, et al.; Bioorg. Med. Chem. Lett. 9, 3335 (1999) Abstract
Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity: L. Meng, et al.; PNAS 96, 10403 (1999) Abstract
Total synthesis of the potent proteasome inhibitor epoxomicin: a useful tool for understanding proteasome biology: N. Sin, et al.; Bioorg. Med. Chem. Lett. 9, 2283 (1999) Abstract
The selective proteasome inhibitors lactacystin and epoxomicin can be used to either up- or down-regulate antigen presentation at nontoxic doses: K. Schwarz, et al.; J. Immunol. 164, 6147 (2000) Abstract
Establishment and some characteristics of epoxomicin (a proteasome inhibitor) resistant variants of the human squamous cell carcinoma cell line, A431: K. Ohkawa, et al.; Int. J. Oncol. 24, 425 (2004) Abstract
Further Categories Containing This Product:
Antitumor Agents (Enzyme Inhibitors) • Proteasome/Related Products • NF-kB Pathway Inhibitors • Anti-inflammatory Agents Other Products • Antibiotics for Inflammation Research • Antibiotics - NF-kB Inhibitors • Antitumor Antibiotics
 
 
ALX-385-032 Revised 16-Jun-08 New product
(R,S)-Equol
Add to Clipboard
SYNONYMS (±)-Equol
3,4-Dihydro-3-(4-hydroxyphenyl)-2H-1-benzopyran-7-ol
4’,7-Dihydroxyisoflavane
PRODUCT LINE Natural Products / Antibiotics
PRODUCT CATEGORY Flavonoids/Related Products
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-385-032-M005   5 mg 30.00 USD Add To Cart
ALX-385-032-M025   25 mg 120.00 USD Add To Cart
Product Specification
FORMULA: C15H14O3
MW: 242.3
CAS NUMBER: 531-95-3, 94105-90-5
MERCK INDEX: 14: 3644
PURITY: ≥98% (HPLC)
APPEARANCE: White to light yellow powder.
SOLUBILITY: Soluble in DMSO, methanol or 100% ethanol; insoluble in water.
SHIPPING: AMBIENT
LONG TERM STORAGE: -20°C
HANDLING: Protect from light.

Product Description

Flavonoid. Racemic mixture. Urinary metabolite of daidzein. Inhibits 12-O-tetradecanoylphorbol 13-acetate (TPA)-induced neoplastic cell transformation by targeting the MEK/ERK/p90RSK/activator protein-1 signalling pathway. Shows positive effects on the incidence of prostate cancer and physiological changes after menopause. Functions as a DHT blocker. Preferentially activates estrogen receptor β (ERβ).
Product Specific Literature References
Comparisons of percent equol producers between prostate cancer patients and controls: case-controlled studies of isoflavones in Japanese, Korean and American residents: H. Akaza, et al.; Jpn. J. Clin. Oncol. 34, 86 (2004) Abstract; Full Text
Mammographic density in relation to daidzein-metabolizing phenotypes in overweight, postmenopausal women: C.L. Frankenfeld, et al.; Cancer Epidemiol. Biomarkers Prev. 13, 1156 (2004) Abstract; Full Text
Equol is a novel anti-androgen that inhibits prostate growth and hormone feedback: T.D. Lund, et al.; Biol. Reprod. 70, 1188 (2004) Abstract; Full Text
Phytoestrogens and their human metabolites show distinct agonistic and antagonistic properties on estrogen receptor alpha (ERalpha) and ERbeta in human cells: S.O. Mueller, et al.; Toxicol. Sci. 80, 14 (2004) Abstract; Full Text
High concordance of daidzein-metabolizing phenotypes in individuals measured 1 to 3 years apart: C.L. Frankenfeld, et al.; Br. J. Nutr. 94, 873 (2005) Abstract
Equol, a metabolite of the soybean isoflavone daidzein, inhibits neoplastic cell transformation by targeting the MEK/ERK/p90RSK/activator protein-1 pathway: N.J. Kang, et al.; J. Biol. Chem. 282, 32856 (2007) Abstract; Full Text
Isoflavones, equol and cardiovascular disease: pharmacological and therapeutic insights: K.A. Jackman, et al.; Curr. Med. Chem. 14, 2824 (2007) Abstract
Further Categories Containing This Product:
ERK1 & ERK2/Related Products • Antitumor Agents (Hormone-related) • Estrogen & Estrogen Receptors/Related Products • Androgens & Androgen Receptors/Related Products
 
 
ALX-380-274 Revised 21-May-08 New product
Erythromycin
Add to Clipboard
PRODUCT LINE Natural Products / Antibiotics
PRODUCT CATEGORY Antibiotics for Inflammation Research
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-380-274-G005   5 g 40.00 USD Add To Cart
Product Specification
FORMULA: C37H67NO13
MW: 733.9
CAS NUMBER: 114-07-8
MERCK INDEX: 14: 3681
RTECS: KF4375000
SOURCE/HOST: Isolated from Streptomyces erythreus.
PURITY: ≥85% (Assay on dry basis)
APPEARANCE: White to off-white powder.
SOLUBILITY: Soluble in water (50mg/ml), 100% ethanol or methanol.
SHIPPING: AMBIENT
LONG TERM STORAGE: -20°C
HAZARD: HARMFUL.

Product Description
Macrolide antibiotic. Inhibits protein synthesis (elongation) at the transpeptidation step. Binds to the 23S RNA of the 50S ribosomal subunit. Effective against Gram-negative and Gram-positive bacteria.
Product Specific Literature References
Inducible erythromycin resistance in bacteria: B. Weisblum; Br. Med. Bull. 40, 47 (1984) Abstract
Erythromycin inhibits transcriptional activation of NF-kappaB, but not NFAT, through calcineurin-independent signaling in T cells: Y. Aoki & P.N. Kao; Antimicrob. Agents Chemother. 43, 2678 (1999) Abstract; Full Text
Assessment of the potential pharmacokinetic and pharmacodynamic interactions between erythromycin and argatroban: J.Q. Tran, et al.; J. Clin. Pharmacol. 39, 513 (1999) Abstract
Inhibition of the metabolism of brotizolam by erythromycin in humans: in vivo evidence for the involvement of CYP3A4 in brotizolam metabolism: T. Tokairin, et al.; Br. J. Clin. Pharmacol. 60, 172 (2005) Abstract; Full Text
Related Products
Further Categories Containing This Product:
NF-kB Pathway Inhibitors • Anti-inflammatory Agents Other Products • Translation Inhibitors
 
 
ALX-270-209 Revised 05-Apr-08
Etoposide
Add to Clipboard
SYNONYMS 4-Desmethylepipodophyllotoxin 9-(4,6-O-ethylidene)-β-D-glucopyranoside
VP-16-213
PRODUCT LINE Natural Products / Antibiotics
PRODUCT CATEGORY Natural Products - Topoisomerase Inhibitors
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-270-209-M025   25 mg 30.00 USD Add To Cart
ALX-270-209-M100   100 mg 65.00 USD Add To Cart
ALX-270-209-M500   500 mg 260.00 USD Add To Cart
Product Specification
FORMULA: C29H32O13
MW: 588.6
CAS NUMBER: 33419-42-0
MERCK INDEX: 14: 3886
RTECS: KC0190000
SOURCE/HOST: Semisynthetic derivative of podophyllotoxin.
PURITY: ≥99%
APPEARANCE: White to off-white powder.
SOLUBILITY: Soluble in DMSO, dimethyl formamide, ethyl ether or chloroform:methanol (1:1); slightly soluble in methanol or acetone; insoluble in water.
SHIPPING: AMBIENT
LONG TERM STORAGE: +20°C
USE/STABILITY: Store solutions in DMSO at 4°C. For long term storage prepare aliquots and store at -20°C.
HANDLING: Protect from light and moisture.
HAZARD: MAY BE CARCINOGENIC. TOXIC.

Product Description
Antitumor reagent. Topoisomerase II inhibitor. Induces apoptosis by FasL. Activates p53 resulting in upregulated expression of TRAIL-R2 (DR5) and Bak to overcome TRAIL resistance in Bax-deficient human colon carcinoma cancer cells.
Product Specific Literature References
The podophyllotoxin derivatives VP16-213 and VM26: B.F. Issell; Cancer Chemother. Pharmacol. 7, 73 (1982) Abstract
Etoposide: four decades of development of a topoisomerase II inhibitor: K.R. Hande; Eur. J. Cancer 34, 1514 (1998) Abstract
Etoposide sensitivity of human prostatic cancer cell lines PC-3, DU 145 and LNCaP: M. Salido, et al.; Histol. Histopathol. 14, 125 (1999) Abstract
A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis: C. Mascaux, et al.; Lung Cancer 30, 23 (2000) Abstract
Distinct pathways for stimulation of cytochrome c release by etoposide: J.D. Robertson, et al.; J. Biol. Chem. 275, 32438 (2000) Abstract; Full Text
Ordering of ceramide formation, caspase activation, and Bax/Bcl-2 expression during etoposide-induced apoptosis in C6 glioma cells: M. Sawada, et al.; Cell Death Differ. 7, 761 (2000) Abstract
Etoposide-induced apoptosis is not associated with the fas pathway in acute myeloblastic leukemia cells: T. Siitonen, et al.; Leuk. Res. 24, 281 (2000) Abstract
Early caspase activation in leukemic cells subject to etoposide-induced G2-M arrest: evidence of commitment to apoptosis rather than mitotic cell death: R.J. Sleiman & B.W. Stewart; Clin. Cancer Res. 6, 3756 (2000) Abstract; Full Text
Cell cycle phase specificity in the potentiation of etoposide-induced DNA damage and apoptosis by KN-62, an inhibitor of calcium-calmodulin- dependent enzymes: M. Aoyama, et al.; Biochem Pharmacol 61, 49 (2001) Abstract
Deacetylase activity associates with topoisomerase II and is necessary for etoposide-induced apoptosis: C.A. Johnson, et al.; J. Biol. Chem. 276, 4539 (2001) Abstract; Full Text
In vitro topo II-DNA complex accumulation and cytotoxicity of etoposide in leukaemic cells from patients with acute myelogenous and chronic lymphocytic leukaemia: Y. Wang, et al.; Leuk. Res. 25, 133 (2001) Abstract
Etoposide: discovery and medicinal chemistry: P. Meresse, et al.; Curr. Med. Chem. 11, 2443 (2004), Review Abstract
Etoposide, topoisomerase II and cancer: E.L. Baldwin & N. Osheroff; Curr. Med. Chem. Anticancer Agents 5, 363 (2005), Review Abstract
Further Categories Containing This Product:
Other Toxins • Antitumor Agents (Enzyme Inhibitors) • Natural Products - Apoptosis Inducers & Inhibitors • Natural Products - Antitumor Reagents • Antitumor Agents (Apoptosis Inducers)